AUG 08, 2016 11:52 AM PDT

Immune-Mediated Neuropathies Caused By Autoantibodies

WRITTEN BY: Kara Marker
Whether chronic or acute, patients with inflammatory nerve disorders are often out of luck for a quick diagnosis or accurate treatment. A new study could soon contribute to improving the circumstances of these patients though: from the University of Wurzburg, researchers are looking at a specific protein as the culprit for some cases of immune-mediated neuropathy.
Credit: faculty.ivytech.edu
Inflammatory nerve disorders develop quickly, often resulting in severe paralysis. There are currently zero diagnostic tests in existence that can accurately diagnose an immune-mediated neuropathies. Patients are then often treated with corticosteroids or antibodies that that have little to no therapeutic effect. Based on results from their current study, published in the journal Brain, and previous studies with similar findings,  Wurzburg scientists recommend a new approach.

In a study of 35 patients with a chronic inflammatory nerve disorder, called chronic inflammatory demyelinating polyneuropathy (CIDP), and 22 patients an acute disorder called Guillain-Barre syndrome, researchers looked for any evidence of autoantibodies targeting a specific component of the nerve fiber called Caspr. This protein helps to build the “Nodes of Ranvier,” a nerve fiber structure that serves as a gap between sections of myelin sheath that forward nerve impulses. 

The myelin sheath acts as an “electrical insulator” that propagates nerve impulses to the attached Nodes of Ranvier, and when antibodies attack Caspr, the structure of the nodes is destroyed and nerve function is rendered drastically impaired.
Credit: www.keyword-suggestions.com
Wurzburg researchers found autoantibodies targeting Caspr in the blood of one patient with CIDP and one patient with Guillain-Barre syndrome. With confirmation of the causation behind these patients’ disease, the researchers successful administered rituximab to inhibit antibody function and reduce the symptoms of their neuropathy. Rituximab is a CD20-directed cytolytic antibody used for treating patients with conditions like non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

Antibodies targeting Caspr proteins may not be the full answer to immune-mediated neuropathies, but researchers from the study believe that antibodies targeting other nerve fiber-related proteins could fill in the gaps of causation. In fact, Caspr is just the third protein in this area of the Nodes of Ranvier for which autoantibodies have been identified. The other two proteins involved with immune-mediated neuropathies include Contactin-1 and Neurofascin-155. Scientists are starting to see that depending on which nerve fiber protein is being targeted by autoantibodies, a patient will exhibit different features.
 
In the future, researchers plan to conduct blood tests for known autoantibodies that target nerve fiber-related proteins, as well as continue to search for other proteins being targeted that cause neuropathies.
 


Sources: Therapeutic Advances in Neurological Disorders, University of Wurzburg, Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th edition, Gene.com
 
About the Author
I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 19, 2022
Coronavirus
Most Omicron-Infected People Are Unaware of Their Infection
AUG 19, 2022
Most Omicron-Infected People Are Unaware of Their Infection
Since the start of the pandemic, researchers and clinicians have warned that not everyone who is infected with SARS-CoV- ...
SEP 04, 2022
Drug Discovery & Development
Brief Exposure to Cancer Drug Produces Anti-aging Effects in Mice
SEP 04, 2022
Brief Exposure to Cancer Drug Produces Anti-aging Effects in Mice
Brief exposure to rapamycin, a promising anti-aging drug, may have similar effects on health and lifespan as longer trea ...
SEP 09, 2022
Health & Medicine
Black-owned Restaurants Disproportionately Impacted by COVID-19
SEP 09, 2022
Black-owned Restaurants Disproportionately Impacted by COVID-19
A new study in the Annals of the American Association of Geographers looked at the impact of COVID-19 on Black-owned bus ...
SEP 29, 2022
Immunology
Friend or Foe? How the Immune System Chooses
SEP 29, 2022
Friend or Foe? How the Immune System Chooses
The immune system has to be able to differentiate between the organisms in our microbiome, which can be helpful and even ...
NOV 01, 2022
Cardiology
Autoimmune Disorders Increase Cardiovascular Risk
NOV 01, 2022
Autoimmune Disorders Increase Cardiovascular Risk
People with autoimmune disorders are significantly more likely to develop heart disease compared to the general populati ...
NOV 28, 2022
Drug Discovery & Development
Construction of the New US-Based Center for Bioprocessing
NOV 28, 2022
Construction of the New US-Based Center for Bioprocessing
Sino Biological is pleased to announce the signing of a lease with Hines and initiation of construction on its new Cente ...
Loading Comments...